Intervention Review

You have free access to this content

Newer generation antidepressants for depressive disorders in children and adolescents

  1. Sarah E Hetrick1,2,*,
  2. Joanne E McKenzie3,
  3. Georgina R Cox1,
  4. Magenta B Simmons1,2,
  5. Sally N Merry4

Editorial Group: Cochrane Common Mental Disorders Group

Published Online: 14 NOV 2012

Assessed as up-to-date: 28 OCT 2011

DOI: 10.1002/14651858.CD004851.pub3


How to Cite

Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD004851. DOI: 10.1002/14651858.CD004851.pub3.

Author Information

  1. 1

    University of Melbourne, Orygen Youth Health Research Centre, Centre for Youth Mental Health, Melbourne, Victoria, Australia

  2. 2

    University of Melbourne, headspace Centre of Excellence, Centre for Youth Mental Health, Melbourne, Victoria, Australia

  3. 3

    Monash University, School of Public Health & Preventive Medicine, Melbourne, Victoria, Australia

  4. 4

    University of Auckland, Department of Psychological Medicine, Auckland, New Zealand

*Sarah E Hetrick, Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10, 35 Poplar Road, Parkville, Melbourne, Victoria, 3054, Australia. shetrick@unimelb.edu.au.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 14 NOV 2012

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Figure 4]
Figure 4. Funnel plot of comparison: 1 Newer generation antidepressant versus placebo (by medication), outcome: 1.2 Remission or response (as defined in trial) LOCF only.
[Figure 5]
Figure 5. Funnel plot of comparison: 1 Newer generation antidepressant versus placebo (by medication), outcome: 1.6 Suicide-related outcome.
[Figure 6]
Figure 6. Contour-enhanced funnel plot for the outcome remission or response (mix of OC and LOCF). The dashed vertical line represents the pooled random-effects estimate
[Figure 7]
Figure 7. Contour-enhanced funnel plot for the suicide-related outcome. The dashed vertical line represents the pooled random-effects estimate
[Figure 8]
Figure 8. Forest plot of comparison: 1 Second generation antidepressant versus placebo (by medication), outcome: 1.1 Depressive symptom severity (CDRS-R).
[Analysis 1.1]
Analysis 1.1. Comparison 1 Newer generation antidepressant versus placebo (by drug), Outcome 1 Depressive symptom severity (CDRS-R).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Newer generation antidepressant versus placebo (by drug), Outcome 2 Remission or response (as defined in trial) LOCF only.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Newer generation antidepressant versus placebo (by drug), Outcome 3 Remission or response (as defined in trial) mix OC and LOCF.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Newer generation antidepressant versus placebo (by drug), Outcome 4 Depressive symptom severity self rated.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Newer generation antidepressant versus placebo (by drug), Outcome 5 Functioning CGAS.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Newer generation antidepressant versus placebo (by drug), Outcome 6 Suicide-related outcome.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Newer generation antidepressant versus placebo (by drug), Outcome 7 Suicidal ideation SIQ-JR.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Newer generation antidepressant versus placebo (by drug), Outcome 8 Adverse events.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Newer generation antidepressant versus placebo (by drug), Outcome 9 Completion of trial protocol.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Newer generation antidepressant versus placebo (child vs adolescent), Outcome 1 Depressive symptom severity (CDRS-R).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Newer generation antidepressant versus placebo (child vs adolescent), Outcome 2 Remission or response (as defined in trial).
[Analysis 2.3]
Analysis 2.3. Comparison 2 Newer generation antidepressant versus placebo (child vs adolescent), Outcome 3 Depressive symptom severity self rated.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Newer generation antidepressant versus placebo (child vs adolescent), Outcome 4 Functioning CGAS.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Newer generation antidepressant versus placebo (child vs adolescent), Outcome 5 Suicide-related outcome.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Newer generation antidepressant versus placebo (child vs adolescent), Outcome 6 Adverse events.